Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1.

Vousden KA, Lundqvist T, Popovic B, Naiman B, Carruthers AM, Newton P, Johnson DJD, Pomowski A, Wilkinson T, Dufner P, de Mendez I, Mallinder PR, Murray C, Strain M, Connor J, Murray LA, Sleeman MA, Lowe DC, Huntington JA, Vaughan TJ.

Sci Rep. 2019 Feb 7;9(1):1605. doi: 10.1038/s41598-019-38842-x.

2.

Late intervention with a myeloperoxidase inhibitor stops progression of experimental chronic obstructive pulmonary disease.

Churg A, Marshall CV, Sin DD, Bolton S, Zhou S, Thain K, Cadogan EB, Maltby J, Soars MG, Mallinder PR, Wright JL.

Am J Respir Crit Care Med. 2012 Jan 1;185(1):34-43. doi: 10.1164/rccm.201103-0468OC.

PMID:
21997333
3.

Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics.

Finch DK, Sleeman MA, Moisan J, Ferraro F, Botterell S, Campbell J, Cochrane D, Cruwys S, England E, Lane S, Rendall E, Sinha M, Walker C, Rees G, Bowen MA, Schneider A, Liang M, Faggioni R, Fung M, Mallinder PR, Wilkinson T, Kolbeck R, Vaughan T, Lowe DC.

J Mol Biol. 2011 Aug 26;411(4):791-807. doi: 10.1016/j.jmb.2011.06.031. Epub 2011 Jun 23.

PMID:
21723291
4.

Engineering a high-affinity anti-IL-15 antibody: crystal structure reveals an α-helix in VH CDR3 as key component of paratope.

Lowe DC, Gerhardt S, Ward A, Hargreaves D, Anderson M, Ferraro F, Pauptit RA, Pattison DV, Buchanan C, Popovic B, Finch DK, Wilkinson T, Sleeman M, Vaughan TJ, Mallinder PR.

J Mol Biol. 2011 Feb 11;406(1):160-75. doi: 10.1016/j.jmb.2010.12.017. Epub 2010 Dec 16.

PMID:
21167836
5.

Identification of a potent anti-IL-15 antibody with opposing mechanisms of action in vitro and in vivo.

Finch DK, Midha A, Buchanan CL, Cochrane D, Craggs RI, Cruwys S, Grahames C, Kolbeck R, Lowe DC, Maltby J, Pattison DV, Vousden KA, Ward A, Sleeman MA, Mallinder PR.

Br J Pharmacol. 2011 Jan;162(2):480-90. doi: 10.1111/j.1476-5381.2010.01061.x.

6.

E. coli expression and purification of human and cynomolgus IL-15.

Ward A, Anderson M, Craggs RI, Maltby J, Grahames C, Davies RA, Finch D, Pattison D, Oakes H, Mallinder PR.

Protein Expr Purif. 2009 Nov;68(1):42-8. doi: 10.1016/j.pep.2009.05.004. Epub 2009 May 10.

PMID:
19435602
7.

Identification of iNOS inhibitors using InteraX.

Mallinder PR, Wallace AV, Allenby G.

J Biomol Screen. 2009 Mar;14(3):263-72. doi: 10.1177/1087057109331476. Epub 2009 Feb 11.

PMID:
19211775
8.

Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase.

Garcin ED, Arvai AS, Rosenfeld RJ, Kroeger MD, Crane BR, Andersson G, Andrews G, Hamley PJ, Mallinder PR, Nicholls DJ, St-Gallay SA, Tinker AC, Gensmantel NP, Mete A, Cheshire DR, Connolly S, Stuehr DJ, Aberg A, Wallace AV, Tainer JA, Getzoff ED.

Nat Chem Biol. 2008 Nov;4(11):700-7. doi: 10.1038/nchembio.115. Epub 2008 Oct 12.

9.

Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2.

Nicholls DJ, Tomkinson NP, Wiley KE, Brammall A, Bowers L, Grahames C, Gaw A, Meghani P, Shelton P, Wright TJ, Mallinder PR.

Mol Pharmacol. 2008 Nov;74(5):1193-202. doi: 10.1124/mol.107.044610. Epub 2008 Aug 1.

PMID:
18676678
10.

Supplemental Content

Loading ...
Support Center